A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NX-5948-301
Phase 1 other active
Quick answer
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies for Relapsed/Refractory B-cell Malignancies is a Phase 1 program (other) at Nurix Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Nurix Therapeutics
- Indication
- Relapsed/Refractory B-cell Malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active